MC2590
Based on 1 publication(s) in Google Scholar
MC2590 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2590 is a inhibitor of HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC50s of 0.015 μM-0.156 μM. MC2590 also inhibits HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with IC50s of 1.35 μM-3.98 μM. MC2625 induces G2/M cell cycle arrest and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction.
For research use only. We do not sell to patients.
- Purity : 98.71%
- CAS No.: 2284460-01-9
- Formula: C20H17N3O3
- Molecular Weight:347.37
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) MC2590
More
Biological Activity
Description
IC50 & Target
[1]|
HDAC1 0.098 μM (IC50) |
HDAC2 0.156 μM (IC50) |
HDAC3 0.039 μM (IC50) |
HDAC6 0.015 μM (IC50) |
HDAC8 0.047 μM (IC50) |
HDAC10 0.071 μM (IC50) |
HDAC4 2.73 μM (IC50) |
HDAC5 1.35 μM (IC50) |
HDAC7 2.06 μM (IC50) |
HDAC9 2.79 μM (IC50) |
HDAC11 3.98 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.32 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 36549114] |
| HCT-116 | IC50 |
0.07 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 36549114] |
| HFF | IC50 |
>10000 nM
Compound: 6
|
Cytotoxicity against HFF
Cytotoxicity against HFF
|
[PMID: 30366254] |
| HL-60 | IC50 |
0.276 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human HL-60 cells incubated for 48 hrs
Antiproliferative activity against human HL-60 cells incubated for 48 hrs
|
[PMID: 36549114] |
| K562 | IC50 |
0.05 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 36549114] |
| KARPAS-299 | IC50 |
0.4 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human KARPAS-299 cells incubated for 48 hrs
Antiproliferative activity against human KARPAS-299 cells incubated for 48 hrs
|
[PMID: 36549114] |
| Kasumi 1 | IC50 |
0.066 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human Kasumi 1 cells incubated for 48 hrs
Antiproliferative activity against human Kasumi 1 cells incubated for 48 hrs
|
[PMID: 36549114] |
| MV4-11 | IC50 |
0.059 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human MV4-11 cells incubated for 48 hrs
Antiproliferative activity against human MV4-11 cells incubated for 48 hrs
|
[PMID: 36549114] |
| NB-4 | IC50 |
0.084 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human NB4 cells incubated for 48 hrs
Antiproliferative activity against human NB4 cells incubated for 48 hrs
|
[PMID: 36549114] |
| OCI-AML2 | IC50 |
0.379 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human OCI-AML2 cells incubated for 48 hrs
Antiproliferative activity against human OCI-AML2 cells incubated for 48 hrs
|
[PMID: 36549114] |
| OCI-AML-3 | IC50 |
0.529 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human OCI-AML-3 cells incubated for 48 hrs
Antiproliferative activity against human OCI-AML-3 cells incubated for 48 hrs
|
[PMID: 36549114] |
| U-937 | IC50 |
0.258 μM
Compound: 5e; MC2590
|
Antiproliferative activity against human U-937 cells incubated for 48 hrs
Antiproliferative activity against human U-937 cells incubated for 48 hrs
|
[PMID: 36549114] |
In Vitro
MC2625 (compound 5e) has antiproliferative activity with Colorectal carcinoma HCT116 (IC50=0.07 μM), Lung adenocarcinoma A549 (IC50=0.32 μM), Chronic myelogenous leukaemia K562 (IC50=0.05 μM) for 72 h[1].
MC2625 (1, 5 μM; 24, 48 h) displays mainly G2/M cell cycle arrest[1].
MC2625 (1, 5 μM; 24, 48 h) reveals H3K9/14 hyperacetylation activity, increases the acetyl-α-tubulin level, markedly upregulates the p21 protein[1].
MC2625 (1, 5 μM; 48 h) increases mRNA expression of p21, BAX and BAK, downregulates cyclin D1 and BCL-2 and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human acute myeloid leukaemia U937 cells
-
Concentration:1, 5 μM
-
Incubation Time:24, 48 h
-
Result:At 24 h, showed very low increase of the pre-G1 peak and led to a G2/M phase arrest at 1 μM; induced a 10% pre-G1 increase and displayed a block at the G2/M phase at 5 μM.
At 48 h, induced a 70-85% block of the cell cycle at the G1 phase.
-
Cell Line:Human acute myeloid leukaemia U937 cells
-
Concentration:1, 5 μM
-
Incubation Time:24, 48 h
-
Result:At 1 μM revealed H3K9/14 hyperacetylation activity, increased the acetyl-α-tubulin level, markedly upregulated the p21 protein.
-
Cell Line:Human acute myeloid leukaemia U937 cells
-
Concentration:1, 5 μM
-
Incubation Time:48 h
-
Result:At 1 μM significantly induced the expression of BAX and BAK, dose-dependently downregulated the antiapoptotic factor BCL-2.
Downregulated miRNAs with antiapoptotic activity (miR-17-5p, miR-18-5p, miR-19b-3p, miR-20a-5p, miR-21-5p); induced the proapoptotic miRNAs (miR-let7a-5p, miR-125b-5p, miR-181a-5p, miR-181b-5p, miR-769-5p, miR-122-5p).
Chemical Information
-
CAS No. 2284460-01-9
-
Appearance Solid
-
Molecular Weight 347.37
-
Formula C20H17N3O3
-
Color Off-white to light yellow
-
SMILES
O=C(NO)/C=C/C1=NC=C(C=C1)NC(CC2=C3C=CC=CC3=CC=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (287.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8788 mL | 14.3939 mL | 28.7877 mL | 71.9694 mL |
| 5 mM | 0.5758 mL | 2.8788 mL | 5.7575 mL | 14.3939 mL | |
| 10 mM | 0.2879 mL | 1.4394 mL | 2.8788 mL | 7.1969 mL | |
| 15 mM | 0.1919 mL | 0.9596 mL | 1.9192 mL | 4.7980 mL | |
| 20 mM | 0.1439 mL | 0.7197 mL | 1.4394 mL | 3.5985 mL | |
| 25 mM | 0.1152 mL | 0.5758 mL | 1.1515 mL | 2.8788 mL | |
| 30 mM | 0.0960 mL | 0.4798 mL | 0.9596 mL | 2.3990 mL | |
| 40 mM | 0.0720 mL | 0.3598 mL | 0.7197 mL | 1.7992 mL | |
| 50 mM | 0.0576 mL | 0.2879 mL | 0.5758 mL | 1.4394 mL | |
| 60 mM | 0.0480 mL | 0.2399 mL | 0.4798 mL | 1.1995 mL | |
| 80 mM | 0.0360 mL | 0.1799 mL | 0.3598 mL | 0.8996 mL | |
| 100 mM | 0.0288 mL | 0.1439 mL | 0.2879 mL | 0.7197 mL |